Clinical Trial Update: TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating an allogeneic CD19-targeting CAR-T cell therapy with TCR reservation and SPPL3 gene knockout (Power3) in relapsed/re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• TCR Reserved and Power3 SPPL3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: RECRUITING